Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Business Crime Defence

Article 159 fraud defence strategy in Russian criminal proceedings in the pharmaceuticals sector: key developments in 2027

Vitaliy Vetrov · July 2026 · 8 min read

Russian prosecutors increasingly target foreign pharma executives under Article 159 fraud. What changed in 2027 and what defence steps matter most. Make an enquiry.

Foreign pharmaceutical executives operating in Russia have faced a demonstrable shift in prosecutorial attention over the past eighteen months: Article 159 of the Russian Criminal Code – the general fraud provision – has become a preferred instrument for investigating commercial disputes, regulatory non-compliance allegations, and pricing irregularities in the pharmaceuticals sector. For expatriate managers and foreign directors of Russian pharma subsidiaries, understanding what changed in early 2027 and how defence strategy must adapt is no longer a precautionary exercise. It is an operational one.

What changed in Russian Article 159 fraud enforcement in the pharmaceuticals sector in 2027?

Russian investigative bodies – principally the Investigative Committee and, in procurement-linked matters, the FSB economic crime units – have accelerated the reclassification of civil and regulatory disputes as criminal fraud under Article 159. The sector-specific shift that became pronounced in 2027 concerns procurement and distribution arrangements for pharmaceutical products on state registers, including those supplied under the essential medicines list. Pricing conduct that was previously the subject of Federal Antimonopoly Service proceedings or Federal Tax Service audit has, in a number of recent matters, been referred to criminal investigation at the pre-trial stage, bypassing the civil and administrative routes entirely.

The operative development is not a statutory amendment to Article 159 itself. The provision's text has not changed. What has shifted is the investigative and prosecutorial interpretation of the deception and misappropriation elements when applied to pharmaceutical distribution contracts, state procurement tenders, and intercompany pricing arrangements between foreign parent entities and their Russian subsidiaries. Investigators have begun treating contract-level price differentials – the margin between import price and state-register price – as potential evidence of deceptive conduct directed at a state counterparty, particularly where the contract counterparty is a state healthcare institution or regional procurement authority.

The second significant development concerns the treatment of regulatory submissions. Documentation submitted to Roszdravnadzor – the Federal Service for Health and Social Development Supervision – in the course of drug registration and pharmacovigilance reporting has been cited in pre-trial materials as supporting a fraud narrative where investigators allege that submissions contained representations that were subsequently contradicted by commercial conduct. Foreign executives who signed off on registration dossiers, clinical trial certifications, or pharmacovigilance updates are among those whose actions have attracted investigative attention.

"What we observe in 2027 is a structural expansion of the Article 159 perimeter in pharmaceuticals: conduct that was commercially and regulatorily routine is being reframed through a criminal lens, and foreign managers find themselves at the intersection of that reframing precisely because they authorised the transactions." — Vitaliy Vetrov, Managing Partner, Vetrov & Partners

If you are a foreign executive or in-house counsel in the Russian pharmaceuticals sector and are aware of investigative attention, make an enquiry in confidence: info@vetrovpartners.com |

Which foreign pharmaceutical executives are most affected by these developments?

The profile of individuals who face elevated exposure under the 2027 enforcement pattern is specific. The risk is concentrated in three categories.

First, general managers and country directors of foreign-owned pharmaceutical subsidiaries registered in Russia who have signatory authority over state procurement contracts or intercompany supply agreements. These individuals are the primary targets of investigative requests for documentation and, in more advanced matters, of restrictions on travel and, in some cases, the initiation of preventive measures.

Second, financial directors and compliance officers who certified pricing structures to state authorities or signed declarations associated with participation in preferential procurement programmes. Where the pricing methodology relied on a transfer pricing analysis prepared by a foreign parent entity, Russian investigators have in several matters sought to attribute responsibility for that analysis to the local certifying signatory.

Third, foreign executives who have already departed Russia but who retain formal positions in Russian legal entities – as nominal directors, registered authorised representatives, or signatories on retained bank accounts. An individual's physical absence from Russian territory does not extinguish criminal process exposure. Investigative actions may proceed, charges may be brought, and in some circumstances a travel restriction order or an international arrest warrant may follow.

The EAEU dimension is relevant: Russia's membership in the Eurasian Economic Union means that pharmaceutical executives who relocate to other EAEU member states – Kazakhstan, Belarus, Armenia, Kyrgyzstan – may face different legal risk from those who relocate to non-EAEU jurisdictions. Coordination of law enforcement actions within the EAEU has increased. This is a factor that defence strategy must account for at an early stage.

Foreign companies holding Russian assets or subsidiaries and managing their Russian legal exposure from abroad should note that the jurisdictional reach of Russian criminal process, in the pharmaceuticals context, now routinely extends to cross-border document requests, notifications to EAEU counterpart authorities, and in some matters to Interpol notice applications. The Business Crime Defence practice at Vetrov & Partners monitors these developments on an ongoing basis.

For firms advising foreign executives with Russian pharmaceutical exposure – discuss the matter in confidence: info@vetrovpartners.com |

What should foreign executives and their advisers do now?

The 2027 pattern calls for a structured response rather than a reactive one. The following steps reflect the current state of Russian criminal defence practice in the pharmaceuticals sector.

First, conduct an internal documentation review before investigators do. In matters where state procurement contracts or essential medicines pricing is in scope, the documentary record – contracts, pricing annexes, intercompany correspondence, regulatory submissions – should be reviewed by Russian-qualified criminal defence counsel before any investigative contact. Documents that could be characterised as containing inconsistent pricing representations are the single most consequential evidential category. A practical guide to Article 159 fraud defence in Russian criminal proceedings sets out the foundational approach to this review.

Second, establish communication protocol with Russian counsel before any investigative contact is made. Investigators in pharmaceuticals fraud matters under Article 159 may approach local employees, subsidiary managers, or retained service providers without notifying the foreign executive directly. A functioning communication line with Russian criminal defence counsel ensures that early-stage investigative actions do not proceed without coordinated legal response.

Third, assess the travel restriction risk before any business travel to Russia or to EAEU member states. This assessment must account for the specific circumstances of the executive's prior role, the stage of any pending investigation, and whether the Russian entity has received any investigative requests or produced documents in related administrative proceedings. For a sector-specific analysis of Article 159 fraud defence strategy applied to pharmaceutical distribution arrangements, see also Article 159 fraud defence strategy in Russian criminal proceedings: the distribution context.

Fourth, review the status of corporate positions held in Russian legal entities. Where a foreign executive no longer operates in Russia but retains a formal position in a Russian pharmaceutical entity, that position should be formally reviewed and, where appropriate, resigned through the correct Russian corporate process. Retention of a formal position without operational awareness carries risk; resignation without proper procedural execution carries different risk. The distinction matters and should be assessed by Russian-qualified counsel.

The current enforcement environment is characterised by pace. Investigators in pharmaceuticals-related Article 159 matters have, in the matters observed, moved from administrative referral to formal investigation status within timeframes that do not allow extended deliberation. For the foreign executive whose first awareness of an investigation is an email from a Russian subsidiary employee or a notification from a bank, the window for structuring an effective defence is shorter than it may appear.

Having Russian-qualified criminal defence counsel who understands both the criminal procedure and the cross-border dimension – including EAEU coordination and the interaction with foreign regulatory and employment obligations – is the practical priority for any executive in this situation.

Discuss your matter in confidence – initial 30-minute meeting complimentary: info@vetrovpartners.com | | asked questionsQ: What specifically changed about Article 159 fraud enforcement in the Russian pharmaceuticals sector in 2027?

A: The Article 159 statute itself was not amended. What changed is the investigative and prosecutorial interpretation of the fraud elements – deception and misappropriation – when applied to pharmaceutical pricing conduct, state procurement arrangements, and regulatory submissions. Investigators have begun treating price differentials between import prices and state-register prices as potential evidence of deceptive intent directed at state counterparties, and regulatory documentation submitted to Roszdravnadzor has been cited in pre-trial materials in support of fraud characterisations. This reclassification of commercially routine conduct into the criminal sphere is the operative development.

Q: Which foreign pharmaceutical executives are affected by the 2027 Article 159 enforcement pattern in Russia?

A: Elevated exposure is concentrated among three categories: general managers and country directors of foreign-owned Russian pharma subsidiaries with signatory authority over state procurement or intercompany supply contracts; financial directors and compliance officers who certified pricing structures to state authorities; and foreign executives who have departed Russia but retain formal positions in Russian legal entities. Physical absence from Russia does not extinguish criminal process exposure. Executives located in other EAEU member states face a distinct and in some respects elevated risk given increased law enforcement coordination within the EAEU.

Q: What is the most important action a foreign pharmaceutical executive should take in response to these developments?

A: The most consequential early-stage action is engaging Russian-qualified criminal defence counsel to conduct a documentation review before any investigative contact occurs. The documentary record – pricing annexes, intercompany correspondence, regulatory submissions – is the primary evidential category in these matters. Beyond documentation, executives should assess travel restriction risk before any movement to Russia or EAEU member states, review the status of any formal positions retained in Russian entities, and establish a communication protocol with Russian counsel so that early-stage investigative actions do not proceed without legal coordination.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry